Tin tức & Cập nhật
Xem bài viết Niệu khoa
Xem
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
21 Nov 2022
Cell-cycle progression tied to metastasis-free survival in high-risk prostate cancer
Cell-cycle progression, but not phosphatase and tensin homolog, appears to significantly elevate the risk of metastasis in men with prostate cancer following Cancer of the Prostate Risk Assessment Post-Surgical adjustment, suggests a study.
Cell-cycle progression tied to metastasis-free survival in high-risk prostate cancer
17 Nov 2022
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.